MPN-328: Pelabresib (CPI-0610) Improved Anemia Associated with Myelofibrosis: Interim Results from the Ongoing MANIFEST Phase 2 Study
Prithviraj Bose1, Srdan Verstovsek1, Marina Kremyanskaya2, John Mascarenhas2, Moshe Talpaz3, Claire Harrison4, Raajit Rampai5, Andrea Patriarca6, Vikas Gupta7, Nikki Granacher8, Tim Somervaille9, Gary Schiller10, Mark Drummond11, Linda Foltz12, Jonathan Lambert13, Witold Prejzner14, Gozde Colak15, Patricia Keller15, James Shao15, Katarina Luptakova15
1The University of Texas MD Anderson Cancer Center, Houston, TX, United States
2Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States
3The University of Michigan, Rogel Cancer Center, Ann Arbor, MI, United States
4Guy's and St Thomas' Hospital, London, United Kingdom
5Memorial Sloan Kettering Cancer Center, New York, NY, United States
6Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia, Novara, Italy
7Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
8Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium
9Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
10David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
11Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
12University of British Columbia, St. Paul’s Hospital, Vancouver, BC, Canada
13University College London Hospitals NHS Foundation Trust, London, United Kingdom
14Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland
15Constellation Pharmaceuticals, Cambridge, MA, United States
Thông tin
Thông tin xuất bản
Clinical Lymphoma, Myeloma and Leukemia
Tập 21
S361-S362
Thông tin tác giả